Winterlight Labs and Genentech Announce New Data in Detecting Longitudinal Change in Alzheimer’s

Article

Winterlight Labs and Genentech have announced new data showing the sensitivity of speech-based digital measures in detecting disease-related longitudinal change in Alzheimer’s disease.

Using data from Genentech’s Tauriel trial of semorinemab in early-stage Alzheimer’s disease (NCT03289143), these analyses provide new evidence that automated measures for assessing patient speech can characterize longitudinal decline with comparable sensitivity to clinician-administered neuropsychological assessments.

Read more about the analysis here.

Recent Videos
Dermasensor
© 2024 MJH Life Sciences

All rights reserved.